Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


4-Antibody appoints new CEO

This article was originally published in Scrip

Executive Summary

Swiss biopharma company 4-Antibody AG has appointed Dr Robert F Burns as chief executive officer. Dr Burns will drive multi-target pharma collaborations, a key goal for the company following its deal with Boehringer Ingelheim last March, whereby it will develop fully human antibodies for a number of targets in a variety of disease indications. Dr Burns previously served as CEO at both human antibody therapeutics research company Affitech A/S and biotech company Celldex Therapeutics.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts